Frontier Genome Medicine: Somatic Editing, Cell Therapy, and Germline Boundaries

The strongest objection is that the same infrastructure built to accelerate genome medicine could normalize biological intervention before society has absorbed the consequences. A critic could argue that once public agencies, firms, and hospitals build the delivery and registry machinery, commercial pressure will push the line from treatment to enhancement and from somatic to heritable editing.

That concern is serious because biomedical markets do push boundaries. The answer is to put the boundary in the policy itself: separate somatic therapy from reproductive germline use, require long-term evidence, enforce against unapproved clinics, and make registry governance visible. The position holds because refusing to build legitimate therapeutic pathways does not stop risky actors; it leaves desperate patients with fewer trustworthy options and more room for fraud.

Patients bear medical risk from conditioning regimens, off-target effects, immune reactions, and uncertain long-term outcomes. Families bear follow-up burden. Public programs and payers bear the cost of expensive curative therapies. Regulators and manufacturers bear the cost of evidence generation and process control. Communities with histories of medical exploitation bear trust costs if access is unequal or consent is weak.

This issue accepts those costs only inside a safety and access framework. Long-term registries, payment models, privacy protections, and enforcement are not side conditions; they are the price of moving frontier therapy into ordinary medicine. The unacceptable cost is pushing patients toward unregulated clinics because legitimate medicine moved too slowly to meet serious need.